AHA video: Intracoronary abciximab not more effective than IV delivery

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Holger Thiele, MD, principal investigator of the AIDA STEMI trial, explained the negative results found in the late-breaking clinical trial, presented at AHA11.

ORLANDO, Fla.—Holger Thiele, MD, principal investigator of the AIDA STEMI trial, explained the results of the negative findings with the trial, when assessing how intracoronary abciximab (ReoPro, Eli Lilly) compared with IV bolus abciximab in STEMI patients treated with primary PCI.

While the randomized, multicenter trial involving more than 2,000 STEMI patients undergoing primary PCI showed that intracoronary abciximab bolus administration is safe, the intracoronary bolus administration did not add benefit with respect to the combined primary study endpoint of death, reinfarction or new congestive heart failure within 90 days.

However, in a video interview with Cardiovascular Businesss, Thiele spoke to some benefits for the heart failure group and the future research in this area.

The video was conducted collaboratively with ClinicalTrialResults.org.